Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Axsome Therapeutics Inc. AXSM

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:AXSM)

Fundamentals Snapshot (NDAQ:AXSM)

Current News (NDAQ:AXSM)

Axsome Therapeutics Announces FDA Approval of AUVELITY(TM), the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

GlobeNewswire 6 hours ago

AXSOME THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM

PR Newswire 6 days ago

Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire 10 days ago

AXSOME THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM

Business Wire July 30, 2022

Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

GlobeNewswire July 28, 2022

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm

Newsfile July 12, 2022

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm

PR Newswire July 12, 2022

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Business Wire July 12, 2022

AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders

PR Newswire July 12, 2022

Bullboard Posts (NDAQ:AXSM)

5 MOST PROMISING ALZHEIMER’S DISEASE STOCK!

5 MOST PROMISING ALZHEIMER’S DISEASE STOCK! https://www.aviseanalytics.com/5-most-promising-alzheimers-disease-stock/
AviseAnalytics - June 22, 2021

RE:Awesome Run to Over $100 USD

Now 74$. First over 100 soon then?
Marphine - February 12, 2021

Awesome Run to Over $100 USD

We did great buying below $10 We think GNPX will do the same if not better :-) Same pattern https://finance.yahoo.com/quote/GNPX?p=GNPX ...
winemerlotcab67 - February 23, 2020